Tagreed Alkaltham: Tranexamic Acid in PBM
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Tranexamic Acid (TXA) in PBM
Not a bleeding drug. A timing decision.
Tranexamic acid is often described as a medication for bleeding. But in Patient Blood Management, TXA is something else entirely. It is a decision about timing.
Bleeding doesn’t usually start out of control. It becomes uncontrolled when early structure is missed.
TXA works best in that narrow window when clot integrity is still protectable, and before bleeding escalates into loss of control.
Used early, TXA protects the newly forming clot from premature breakdown. Used late, it can only limit further damage.
From a PBM perspective, TXA is not about stopping blood loss after it happens. It’s about preventing escalation.
When given at the right time, TXA:
- preserves clot integrity
- reduces escalation
- lowers transfusion needs
Not because it replaces blood but because it protects the system from needing more of it.
From a Blood Bank Perspective:
TXA is not seen as a bleeding medication. It is seen as an early stabilizing decision.
When TXA is administered early, it often prevents the rapid cascade that follows uncontrolled bleeding: massive transfusion activation, sudden inventory pressure, and reactive decisions made under urgency rather than design.
Early TXA preserves more than clot integrity. It preserves options.
It allows the blood bank to respond within a controlled, balanced framework, instead of being pulled abruptly into crisis mode.
When TXA is delayed, the blood bank is rarely responding to bleeding alone, it is responding to escalation, narrowed choices, and loss of control.
PBM doesn’t fail when bleeding occurs. It fails when early decisions are delayed.
And TXA reminds us of a simple truth:
Timing is the intervention before blood is needed.”
Find more posts featuring Tagreed Alkaltham on Hemostasis Today.
-
Mar 9, 2026, 14:26Augustina Isioma Ikusemoro: Women Powering the Future of Blood Transfusion
-
Mar 9, 2026, 14:10Jecko Thachil: The Journey of Protamine – From Heparin Reversal to Potential Gene Therapy Applications
-
Mar 9, 2026, 14:10Advocating for the Bleeding Disorders Community at NBDF 2026 Washington Days – Hemophilia of Georgia
-
Mar 9, 2026, 14:05Ramy Abdelnaby: The Impact of Multiterritory Brain Infarcts on Recurrent Stroke Risk and Anticoagulation Efficacy
-
Mar 9, 2026, 13:55Marios Georgakis: GLP-1 Receptor Agonism as a Promising Approach for cSVD
-
Mar 9, 2026, 13:54Ahmed Ibrahim: Optimal Antithrombotic Therapy for Secondary Stroke Prevention in Patients with AF and ASCVD
-
Mar 9, 2026, 13:49Rick Matthews: Looking Beyond Clot Clearance in Long-Term Management After DVT
-
Mar 9, 2026, 13:43Genetic Technologies for Hemophilia Information Sheet Now Available in French and Spanish – WFH
-
Mar 9, 2026, 13:38Challenges in Hemophilia Care and Access to Treatment in Pakistan – Hemophilia Welfare Society Karachi Pakistan